Matinas BioPharma MTNB 深 滬
已收盤 08-07 16:00:00 美东时间
0.283
+0.015
+5.44%
華盛通- 最 高0.283
- 今 開0.2603
- 成交量 116.00万股
- 最 低 0.2496
- 昨 收 0.2684
- 總市值 181.30万
- 52周最高 2.2422
- 市盈率 靜 --
- 換手率 18.11%
- 52周最低 0.2312
- 委 比 0.00%
- 總股本 640.62万
- 歷史最高 197.50
- 量 比 1.08
- 振 幅 12.44%
- 歷史最低 0.2312
- 每 手 1
- 風險率 0.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BTIG Terminates Sales Agreement With Matinas BioPharma, Effective Immediately On July 23; Incurs No Termination Penalties Or Expenses From Sales Agreement Termination
As previously disclosed, on July 2, 2020, Matinas BioPharma Holdings, Inc. (the "Company") entered into an At-The-Market Sales Agreement (the "Sales Agreement") with BTIG, LLC ("BTIG"), pursuant to which the Company could offer and sell shares of its common stock, par value $0.0001 per share ("Commo...
07-25 05:11
Matinas Biopharma Holdings shares are trading lower. The company announced it entered into a definitive purchase agreement to sell Matinas BioPharma Nanotechnologies, Inc., including MAT220 to Azurity Pharmaceuticals.
Matinas Biopharma Holdings shares are trading lower. The company announced it entered into a definitive purchase agreement to sell Matinas BioPharma Nanotechnologies, Inc., including MAT220 to Azurity Pharmaceuticals.
07-13 20:48
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
Matinas BioPharma Holdings, Inc. has entered into a definitive business combination agreement with GH Power Inc. to create a publicly traded clean energy company focused on modular carbon-free energy, green hydrogen, and critical materials. The transaction is expected to provide a public market platform to accelerate commercialization and growth across North America and Europe. Additionally, Matinas has agreed to sell its subsidiary, Matinas BioP...
07-13 12:00
Matinas BioPharma Granted NYSE American Compliance Extension
The latest announcement is out from Matinas BioPharma ( ($MTNB) ). On June 24, ...
06-27 05:52
Matinas BioPharma faces NYSE notice over equity shortfall; gets until 2027 to comply
Matinas BioPharma (MTNB) announced on Friday that it received a notice from NYSE American for not meeting the exchange's minimum shareholder equity requirement. The company's shareholder equity fell t...
06-27 05:38
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
Matinas BioPharma Holdings received a notice from NYSE American regarding non-compliance with listing standards due to insufficient stockholders' equity and recent losses. The company submitted a plan to regain compliance by October 2, 2027, which was accepted by NYSE American. Shares will remain listed during the plan period, subject to periodic reviews. The notice does not affect the company's operations or SEC reporting. Matinas BioPharma focu...
06-26 21:15
Matinas BioPharma Hldgs Q1 EPS $(0.30) Up From $(0.33) YoY
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.30) per share. This is a 9.09 percent increase over losses of $(0.33) per share from the same period last year.
05-09 06:07
